25
May

08:00 AM ET

Clinical Operations

Name: Clinical Operations Strategy Meeting Princeton
Start: 2023-05-25T08:00
End: 2023-05-25T17:50
Location: Hyatt Regency Princeton

Strategy Meeting East Coast USA 2023

Effective integration of patient outcomes in clinical trial design, Overcoming under-enrollment of ethnic minorities, Employing RBQM and deep learning to your Trial knowledge

Hyatt Regency Princeton

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Clinical Operations Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s Clinical Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Clinical Operations professionals from across the East Coast, in Princeton, New Jersey, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day.

Adriana Comprelli

Executive Director, Therapeutic Area Head, Clinical Operations Strategy Bristol Myers Squibb

Alex Zisson

Managing Director H.I.G. Capital

Amy Neubauer

Director, GCDM Operational Excellence Alexion Pharmaceuticals

Christopher J. Schaber

Chairman, President & Chief Executive Officer Soligenx

Christopher J. Schaber, PhD has over 30 years experience in the pharmaceutical and biotechnology industry.  Dr. Schaber has been Soligenix’s Chairman, President and Chief Executive Officer and a director since August 2006. He also serves on the board of directors for the Biotechnology Council of NJ (BioNJ), where he was a Past Chair.  He has been a member of the corporate councils for both the National Organization for Rare Disorders (NORD) and the American Society for Blood and Marrow Transplantation (ASBMT).  Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations.  From 1996 to 1998, he was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, he was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA from Western Maryland College, his MS in Pharmaceutics from Temple University School of Pharmacy and his PhD in Pharmaceutical Sciences from the Union Graduate School.  During his career, Dr. Schaber has played a significant role in raising in excess of $350 million through both public offerings and private placements, as well as approximately $100 million in non-dilutive funding awards from state and federal governmental agencies.

Craig Granowitz

Chief Medical Officer Lexicon Pharmaceuticals

Gayle Wittenberg

VP, Neuroscience Data Science and Digital Health Janssen R&D

Jennifer Sheller

AVP Clinical Operations Merck & Co

Karen Correa

Vice President, Head Global Clinical Operations Takeda

Katherine Taylor

Head Risk Evaluation and Adaptive Integrated Monitoring Merck & Co

Kelly Clark

Head of US Partnerships and Global Site Development Merck & Co

Laura Vessey

Director in Early Development Oncology Janssen

Lorie Crowe

Program Director, Global Trial Optimization Merck & Co

Mark Travers

VP, Head of GCTO Regions & Regional Operations, Global Clinical Trial Operations Merck & Co

Matthew Rosenberg

Advisor Guxi Capital

Michael Walega

Head of Centralized Monitoring Bristol Myers Squibb

Michele Sharr-Hyde

Early Clinical Development and Hematology Clinical Science Head Daiichi-Sankyo

Paul Blake

Chief Executive Officer Papyrus Therapeutics Inc

Saikat Nandi

Global Chief Business Officer Oryzon Genomics SA

Seasoned investment executive, business operator and entrepreneur with over 15 years of buy-side and operational experience in the healthcare, technology and finance industries. Has managed public and private investments totaling more than $1 billion and has helped build over 20 life science and technology companies. Served on the Board of Directors of Atomwise, Cullinan Oncology (NASDAQ: 
CGEM), ElevateBio, Fractyl Health, Roivant Sciences (NASDAQ: ROIV), SQZ (NYSE: SQZ). As Global Chief Business Officer at Oryzon, manages cross-functional teams across financing, M&A, business development and operations. As a Portfolio Manager at AIG Asset Management, oversaw AIG’s healthcare & life sciences investments across venture capital, private equity, hedge fund and debt securities. Previously served as Healthcare Investment Advisor at a global multi-family office managing venture and growth equity investments and prior to that served as Business Development Consultant at the New York State Center for Biotechnology, overseeing strategic partnerships and capital raising activities. Holds a Visiting Scientist position at the Cold Spring Harbor Laboratory (CSHL) and serves as reviewer & board member of several portfolio companies, federal funding agencies, scientific journals & philanthropic organizations. Received D.Phil. (Ph.D.) from Oxford University & several awards, honors & research grants. Authored over two dozen articles & books. Multilingual, avid dog lover and has lived and worked in North America, Europe and Asia.

Seun Makinde

Associate Director Clinical Development Shionogi

Victoria Gamerman

Global Head of Data Governance and Insights Boehringer Ingelheim

Victoria Gamerman PhD is the Global Head of Data Governance and Insights at Boehringer Ingelheim, in the digital transformation center of excellence. She is accountable for shaping the pharmaceutical giant’s data strategy and data governance for clinical development and operations. She was previously the company’s Head of Health Informatics and Analytics, leading a team of experts in advanced statistical methodologies to generate evidence from external clinical data and real-world healthcare data to support drug development.Dr Gamerman is focused on improving healthcare by connecting the dots between patient-centricity, digital health and real-world evidence to evolve clinical research through innovation and digital transformation. 
She earned her master’s and doctorate in biostatistics from the University of Pennsylvania’s School of Medicine and has a master’s in mathematics from Boston University Pennsylvania’s School of Medicine, and a MA and BA in Mathematics from Boston University.

Srinivasan Vairavan

Director, Data Science and Digital Health Janssen R&D

Aruna Adhikari Thapa

Senior Director, Product Management IQVIA Technologies

Rachael Geedey

Associate Director RBQM Technology IQVIA Technologies

Gary Shorter

Head of Research and Development of AI into Products IQVIA Technologies

Sarrah Val

MPH Vice President of Global Sales MD GROUP

Varun Nagpal

Medical Director Eisai US

First name	Last name	Job title	Company name	Photo URL	Bio Position
Adriana	Comprelli	Executive Director, Therapeutic Area Head, Clinical Operations Strategy	Bristol Myers Squibb	https://proventainternational.com/wp-content/uploads/2023/03/Adriana-Comprelli.jpg
Alex	Zisson	Managing Director	H.I.G. Capital	https://proventainternational.com/wp-content/uploads/2023/03/Alex-Zisson.jpg
Amy	Neubauer	Director, GCDM Operational Excellence	Alexion Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2023/03/Amy-Neubauer.jpg
Christopher	J. Schaber	Chairman, President & Chief Executive Officer	Soligenx	https://proventainternational.com/wp-content/uploads/2023/04/Christopher-Schaber.jpg	Christopher J. Schaber, PhD has over 30 years experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been Soligenix’s Chairman, President and Chief Executive Officer and a director since August 2006. He also serves on the board of directors for the Biotechnology Council of NJ (BioNJ), where he was a Past Chair. He has been a member of the corporate councils for both the National Organization for Rare Disorders (NORD) and the American Society for Blood and Marrow Transplantation (ASBMT). Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations. From 1996 to 1998, he was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, he was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA from Western Maryland College, his MS in Pharmaceutics from Temple University School of Pharmacy and his PhD in Pharmaceutical Sciences from the Union Graduate School. During his career, Dr. Schaber has played a significant role in raising in excess of $350 million through both public offerings and private placements, as well as approximately $100 million in non-dilutive funding awards from state and federal governmental agencies.
Craig	Granowitz	Chief Medical Officer	Lexicon Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2023/03/Craig-Granowitz.jpg
Gayle	Wittenberg	VP, Neuroscience Data Science and Digital Health	Janssen R&D	https://proventainternational.com/wp-content/uploads/2023/03/Gayle-Wittenberg.jpg	Gayle is Head of Neuroscience Data Science and Digital Health at Janssen R&D, integrating DS/DH end-to-end along the pharmaceutical value chain. She holds a PhD in Neuroscience from Princeton and B.S in Physics and B.S. in Engineering Physics from Oregon State. She worked in Proteomics at BMS and led the Personalized Healthcare group at Siemens Corporate Research before joining Janssen in 2011 as Director of Integrative Solutions. Subsequently she held positions as Head of Translational Research and Precision Medicine Research IT (2016) and Head Intelligent Automation Pharm IT (2019). Her focus is bringing the right medicine to the right patient.
Jennifer	Sheller	AVP Clinical Operations	Merck & Co	https://proventainternational.com/wp-content/uploads/2023/04/Jennifer-Sheller.jpg
Karen	Correa	Vice President, Head Global Clinical Operations	Takeda	https://proventainternational.com/wp-content/uploads/2023/02/correa.png
Katherine	Taylor	Head Risk Evaluation and Adaptive Integrated Monitoring	Merck & Co	https://proventainternational.com/wp-content/uploads/2023/04/KathyTaylor.jpg
Kelly	Clark	Head of US Partnerships and Global Site Development	Merck & Co	https://proventainternational.com/wp-content/uploads/2023/04/Kelly-Clark.jpg
Laura	Vessey	Director in Early Development Oncology	Janssen	https://proventainternational.com/wp-content/uploads/2022/09/laura-vessey-1.jpg	Laura Vessey is a Director in Early Development Oncology at Janssen where she is a manager responsible for the operational delivery of the early oncology clinical portfolio. Over the past 30 years, Laura has focused her career in Early Clinical Development from Phase 0 through Phase IIa in oncology, neuroscience, cardiometabolic, immunology, and infectious disease. She began her career at The Upjohn Company (now Pfizer) as a chemist in the lab and then early clinical development, she moved to Merck where she was involved in multiple therapeutic areas for over twenty years, and is now at Janssen focusing on early clinical oncology. Laura holds a B.S degree from Hope College in Michigan and resides with her family in Princeton, NJ.
Lorie	Crowe	Program Director, Global Trial Optimization	Merck & Co	https://proventainternational.com/wp-content/uploads/2023/04/Lorie-Crowe.jpg
Mark	Travers	VP, Head of GCTO Regions & Regional Operations, Global Clinical Trial Operations	Merck & Co	https://proventainternational.com/wp-content/uploads/2023/04/MARK-TRAVERS.jpg
Matthew	Rosenberg	Advisor	Guxi Capital	https://proventainternational.com/wp-content/uploads/2023/04/Matthew-Rosenberg.jpg
Michael	Walega	Head of Centralized Monitoring	Bristol Myers Squibb	https://proventainternational.com/wp-content/uploads/2023/03/Michael-Walega.jpg
Michele	Sharr-Hyde	Early Clinical Development and Hematology Clinical Science Head	Daiichi-Sankyo	https://proventainternational.com/wp-content/uploads/2023/03/Michele-Sharr.jpg
Paul	Blake	Chief Executive Officer	Papyrus Therapeutics Inc	https://proventainternational.com/wp-content/uploads/2023/03/Paul-Blake.jpg
Saikat	Nandi	Global Chief Business Officer	Oryzon Genomics SA	https://proventainternational.com/wp-content/uploads/2023/03/Sai_Nandi.jpg	Seasoned investment executive, business operator and entrepreneur with over 15 years of buy-side and operational experience in the healthcare, technology and finance industries. Has managed public and private investments totaling more than $1 billion and has helped build over 20 life science and technology companies. Served on the Board of Directors of Atomwise, Cullinan Oncology (NASDAQ: CGEM), ElevateBio, Fractyl Health, Roivant Sciences (NASDAQ: ROIV), SQZ (NYSE: SQZ). As Global Chief Business Officer at Oryzon, manages cross-functional teams across financing, M&A, business development and operations. As a Portfolio Manager at AIG Asset Management, oversaw AIG’s healthcare & life sciences investments across venture capital, private equity, hedge fund and debt securities. Previously served as Healthcare Investment Advisor at a global multi-family office managing venture and growth equity investments and prior to that served as Business Development Consultant at the New York State Center for Biotechnology, overseeing strategic partnerships and capital raising activities. Holds a Visiting Scientist position at the Cold Spring Harbor Laboratory (CSHL) and serves as reviewer & board member of several portfolio companies, federal funding agencies, scientific journals & philanthropic organizations. Received D.Phil. (Ph.D.) from Oxford University & several awards, honors & research grants. Authored over two dozen articles & books. Multilingual, avid dog lover and has lived and worked in North America, Europe and Asia.
Seun	Makinde	Associate Director Clinical Development	Shionogi	https://proventainternational.com/wp-content/uploads/2023/04/Seun-Makinde.jpg
Victoria	Gamerman	Global Head of Data Governance and Insights	Boehringer Ingelheim	https://proventainternational.com/wp-content/uploads/2023/05/Gamerman.jpg	Victoria Gamerman PhD is the Global Head of Data Governance and Insights at Boehringer Ingelheim, in the digital transformation center of excellence. She is accountable for shaping the pharmaceutical giant’s data strategy and data governance for clinical development and operations. She was previously the company’s Head of Health Informatics and Analytics, leading a team of experts in advanced statistical methodologies to generate evidence from external clinical data and real-world healthcare data to support drug development.Dr Gamerman is focused on improving healthcare by connecting the dots between patient-centricity, digital health and real-world evidence to evolve clinical research through innovation and digital transformation. She earned her master’s and doctorate in biostatistics from the University of Pennsylvania’s School of Medicine and has a master’s in mathematics from Boston University Pennsylvania’s School of Medicine, and a MA and BA in Mathematics from Boston University.
Srinivasan	Vairavan	Director, Data Science and Digital Health	Janssen R&D	https://proventainternational.com/wp-content/uploads/2023/04/Srinivasan-Vairavan.jpg
Aruna	Adhikari Thapa	Senior Director, Product Management	IQVIA Technologies	https://proventainternational.com/wp-content/uploads/2022/10/Aruna-Adhikari-Thapa-2.jpg	Aruna Adhikari-Thapa is a seasoned technology strategist with 20+ years’ experience in software product management. She excels in leading cross-functional teams, shaping product strategies, justifying investments, and launching innovative solutions to address complex business challenges. Aruna holds a B.Sc. in Network Modeling & Simulation and Statistics from Saint Cloud State University, along with an MBA in Strategic Technology Management from Augsburg College. Aruna’s career is marked by her commitment to delivering innovative solutions creating maximum value for end users. She was recently named to the PharmaVoice 100 in the Tech and AI Wizard category.
Rachael	Geedey	Associate Director RBQM Technology	IQVIA Technologies	https://proventainternational.com/wp-content/uploads/2022/11/Rachael-Geedey.jpg	Rachael brings expertise in technology training, adoption and implementation across various clinical trial platforms. She is passionate about people, process and technology and has extensive operational experience supporting study teams in the use of RBQM technology. Rachael is currently an Associate Director supporting IQVIA’s Risk Based Quality Management SaaS Solution.
Gary	Shorter	Head of Research and Development of AI into Products	IQVIA Technologies	https://proventainternational.com/wp-content/uploads/2022/03/Gary-Shorter-1.jpg	Gary pursues the use of emerging technology to provide new and more efficient capabilities to enhance clinical trial management. This includes development of new design software through to more recent advancements with AI/ML capabilities where his team has developed several micro-products and micro-services that can be plugged in and used by any SaaS solution.
Sarrah	Val	MPH Vice President of Global Sales	MD GROUP	https://proventainternational.com/wp-content/uploads/2022/02/Sarrah-Val.jpg	Earned her Masters in Public Health from the University of Southern California after completing a dual degree in Integrative Physiology and Mathematics from the University of Colorado, Boulder. She is driven by her love for patient care, and invests her industry efforts into making clinical trials more accessible, equitable, and patient-focused. With prior experience in Medical Affairs and as a Director of Clinical Operations, she has led clinical trials from protocol design through FDA approval, driven physician education initiatives, and facilitated post-market and investigator grant research.
Varun	Nagpal	Medical Director	Eisai US	https://proventainternational.com/wp-content/uploads/2023/05/Varun-Nagpal.jpg

Adriana Comprelli, Alex Zisson, Amy Neubauer, Christopher J. Schaber, Craig Granowitz, Gayle Wittenberg, Jennifer Sheller, Karen Correa, Katherine Taylor, Kelly Clark, Laura Vessey, Lorie Crowe, Mark Travers, Matthew Rosenberg, Michael Walega, Michele Sharr-Hyde, Paul Blake, Saikat Nandi, Seun Makinde, Victoria Gamerman, Srinivasan Vairavan, Aruna Adhikari Thapa, Rachael Geedey, Gary Shorter, Sarrah Val, Varun Nagpal

See the agenda and facilitator line-up. Download the strategy meeting brochure for full details.

DOWNLOAD BROCHURE

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

There’s only so much you can learn from presentations and lectures. Instead, our interactive Roundtable Discussions let you debate the topics that really matter.

Senior Decision Makers

All our Strategy Meetings are aimed at director-level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard.

Personalised Agendas

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you.

Private and Intimate Networking

Small group discussions, private meetings, networking drink – however you choose to make those important connections, our Strategy Meetings have the solution.

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

09:00

Roundtable Tracks

Risk Based Quality Management/Central & Remote Monitoring Choosing The Most Effective Monitoring Strategy To Improve Participant and Site Compliance And Data Reliability -Michael Walega Head of Centralized Monitoring, Bristol Myers Squibb Diversity, Equity, and Inclusion in Patient Engagement/Decentralised Trials Outlining the strategies for supporting more robust engagement in communities hence improving clinical trial diversity -Karen Correa Vice President, Head Global Clinical Operations Takeda Emerging Biopharma Challenges And Opportunities In Early-Stage Biotech Funding Understand the strategies startupsneed to stand out from the competition -Paul Blake Chief Executive Officer Papyrus Therapeutics Inc Digital Measurements/ Clinical Data Promoting Diversity in Clinical Trials: organizational challenges and opportunities -Seun Makinde Associate Director Clinical Development, Shionogi Global Site Selection and Feasibility Study Identifying Your Sites by Examining Selection Criteria and Site Performance: What Selection Criteria May Inhibit Your Clinical Trial’s Success? -Adriana Comprelli Therapeutic Area Head, Clinical Operations Strategy Bristol Myers Squibb -Lorie Crowe Program Director, Global Trial Optimization Merck & Co Investment,Private Equity & Venture Capital EtPartnerships How Wall Street’s Roller Coaster Ride is Affecting the CRO/CDMO Ecosystem -Alex Zisson Managing Director, H.I.G. Capital

11:10

Roundtable Tracks

Risk Based Quality Management/Central & Remote Monitoring Exploring Important Trends in RBQM: A Comprehensive Overview -Rachel Geedy Associate Director RBQM Technology, IQVIA Diversity, Equity, and Inclusion in Patient Engagement/Decentralised Trials Increasing diversity in clinical trials requires redesigning our approach -Sarrah Val MPH Vice President of Global Sales, MD GROUP Emerging Biopharma Increasing diversity in clinical trials requires redesigning our approach Digital Measurements/ Clinical Data How advanced AI technologies such as Intelligent Document Review and generative AI, Chat GPT can help Pharma accelerate filings -Gary Shorter Head of Research and Development of AI into Products, IQVIA Global Site Selection and Feasibility Study Overcoming Inertia to Accelerate Study Start-Up -Aruna Adhikari Thapa Senior Director of Product Strategy and Product Management, IQVIA Clinical Technologies Investment, Private Equity & Venture Capital Partnerships

13:40

Roundtable Tracks

Risk Based Quality Management/Central & Remote Monitoring A Developed Risk-Based Quality Management Approach To Mitigate Potential Risks and Liabilities -Amy Neubauer Director, GCDM Operational Excellence, Alexion Pharmaceuticals Diversity, Equity, and Inclusion in Patient Engagement/Decentralised Trials How Can We Recognize And Eliminate Obstacles That Prevent Minority Involvement, Such As Historical Distrust, Accessibility Issues, And A Lack of Awareness -Jennifer Sheller AVP Clinical Operations, Merck & Co -Kelly Clark Head of US Partnerships and Global Site Development, Merck & Co Emerging Biopharma Clinical Development Perspective on: “What options are available to biopharma companies that face unique challenges due to their size and scale? -Amanda McEwen Vice President, Clinical Development, Salubris Biotherapeutics Digital Measurements/ Clinical Data How can state of the art data analytics transform clinical trials? What obstacles exist? -Sonia S. Cawley Global Head, Analytics Innovation, Boehringer Ingelheim Global Site Selection and Feasibility Study Robust and Actionable Site Responses: Improve the accuracy of feasibility survey responses by Establishing a precise method to collect and analyze relevant and actionable data -Laura Vessey Senior Director, Head of Early Development and Clinical Pharmacology, Janssen Investment, Private Equity & Venture Capital Partnerships Why are CRO M&A deals on the rise? How expanding full service capabilities, through a strategic M&A process brings global efficiencies to sponsors -Matthew Rosenberg Advisor, Guxi Capital

15:50

Roundtable Tracks

Risk Based Quality Management/Central & Remote Monitoring Enhancing Trial Knowledge And Driving Better Outcomes By Using RBQM And Deep Learning -Katherine Taylor Head Risk Evaluation and Adaptive Integrated Monitoring, Merck & Co Diversity, Equity, and Inclusion in Patient Engagement/Decentralised Trials Redesigning Clinical Trials: Patient Perspectives; Enhancing Inclusivity; Leveraging AI -Craig Granowitz Chief Medical Officer, Lexicon Pharmaceuticals -Tracy Newbold VP Clinical Operations, Lexicon Pharmaceuticals Emerging Biopharma What future developments and commercial realities businesses with concentrated pipelines or single assets are facing? -Christopher J. Schaber Chairman, President & Chief Executive Officer, Soligenx Digital Measurements/ Clinical Data Realizing Value and Impact to Clinical Development Programs from Data Derived from Digital Technologies In Clinical Trials -Gayle Wittenberg VP, Neuroscience Data Science and Digital Health, Janssen R&D -Srinivasan Vairavan Director, Data Science and Digital Health, Janssen R&D Global Site Selection and Feasibility Study What are the biggest feasibility errors that even the most experienced sponsors occasionally make and how can we have a hands on approach to avoid these mistakes? -Michele Sharr-Hyde Executive Director, Head Clinical Science, DaiichiSankyo Investment, Private Equity & Venture Capital Partnerships Why are the big Pharmas relying on partnerships and acquisitions to access new innovations and expand their pipelines? -Saikat Nandi Global Chief Business Officer, Oryzon Genomics SA

Become an official strategy meeting partner. Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say…

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Clinical Trials Princeton

Clinical Operations & Clinical Trial Supply Chain Strategy Meeting East Coast 2024

Clinical Operations

Strategy Meeting East Coast USA 2023

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Hyatt Regency Princeton

Fresh Clinical Operations Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Facilitators

Adriana Comprelli

Alex Zisson

Amy Neubauer

Christopher J. Schaber

Craig Granowitz

Gayle Wittenberg

Jennifer Sheller

Karen Correa

Katherine Taylor

Kelly Clark

Laura Vessey

Lorie Crowe

Mark Travers

Matthew Rosenberg

Michael Walega

Michele Sharr-Hyde

Paul Blake

Saikat Nandi

Seun Makinde

Victoria Gamerman

Srinivasan Vairavan

Aruna Adhikari Thapa

Rachael Geedey

Gary Shorter

Sarrah Val

Varun Nagpal

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

Opening Keynote

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

Roundtable

Roundtable Tracks

Networking Lunch

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

Keynote Presentations

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

Drinks Reception

Our Lead Sponsor

Our Co-Host Sponsor

Key Opinion Leader

Press play to hear what your colleagues had to say…

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

Hyatt Regency Princeton